Please use this identifier to cite or link to this item:
https://islhd.intersearch.com.au/islhdjspui/handle/1/6280| Title: | Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study |
| ISLHD Author: | Miyakis, Spiros |
| Authors: | Essink BJ;Shapiro C;Isidro MGD;Bradley P;Pragalos A;Bloch M;Santiaguel J;Frias MV;Miyakis S;Alves de Mesquita M;Berrè S, Servais C;Waugh N;Hoffmann C, Baba E;Schönborn-Kellenberger O;Wolz OO;Koch SD;Ganyani T;Boutet P;Mann P;Mueller SO;Ramanathan R;Gaudinski MR;Vanhoutte N |
| Keywords: | Vaccine;Covid 19 |
| Date Published: | 31-Oct-2024 |
| Citation: | Hum Vaccin Immunother. 2024 Dec 31;20(1):2408863. doi: 10.1080/21645515.2024.2408863. Epub 2024 Oct 18. |
| URI: | https://islhd.intersearch.com.au/islhdjspui/handle/1/6280 |
| DOI: | 10.1080/21645515.2024.2408863 |
| Journal Title: | Hum Vaccin Immunother |
| Appears in Collections: | Research publications from current and former ISLHD staff. |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.